CY1113646T1 - THE CRYSTAL FORM OF A BINDING UNION - Google Patents

THE CRYSTAL FORM OF A BINDING UNION

Info

Publication number
CY1113646T1
CY1113646T1 CY20131100115T CY131100115T CY1113646T1 CY 1113646 T1 CY1113646 T1 CY 1113646T1 CY 20131100115 T CY20131100115 T CY 20131100115T CY 131100115 T CY131100115 T CY 131100115T CY 1113646 T1 CY1113646 T1 CY 1113646T1
Authority
CY
Cyprus
Prior art keywords
salt
crystal form
hydroxy
union
binding
Prior art date
Application number
CY20131100115T
Other languages
Greek (el)
Inventor
Robert S Chao
Miroslav Rapta
Pierre-Jean Colson
Original Assignee
Theravance, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05803280A external-priority patent/EP1778672B1/en
Application filed by Theravance, Inc. filed Critical Theravance, Inc.
Publication of CY1113646T1 publication Critical patent/CY1113646T1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η εφεύρεση παρέχει ένα κρυσταλλικό άλας 1,2-αιθανοδισουλφονικού οξέος του διφαινύλ-2-υλκαρβαμικού οξέος 1-[2-(2-χλώρο- 4-{[(R)-2-υδρόξυ- 2-(8-υδρόξυ- 2-όξο- 1,2-διϋδροκινολιν-5-ύλ) αιθυλαμίνο] μεθυλ}- 5-μεθοξυφαινυλκαρβαμόυλ) αιθύλ] πιπεριδιν-4-ύλ εστέρα ή ενός επιδιαλυτωμένου άλατος αυτού. Η παρούσα εφεύρεση παρέχει επίσης φαρμακευτικές συνθέσεις που περιέχουν ένα τέτοιο άλας ή που παρασκευάζονται χρησιμοποιώντας ένα τέτοιο άλας, διαδικασίες και ενδιάμεσα για τη παρασκευή ενός τέτοιου άλατος, και μεθόδους χρήσης ενός τέτοιου άλατος για την αντιμετώπιση μιας πνευμονικής διαταραχής.The invention provides a crystalline salt of diphenyl-2-ylcarbamic acid 1,2-ethanedisulfonic acid salt of 1- [2- (2-chloro-4 - {[(R) -2-hydroxy-2- (8-hydroxy-2-)) oxo-1,2-dihydroquinolin-5-yl) ethylamino] methyl} - 5-methoxyphenylcarbamoyl) ethyl] piperidin-4-yl ester or a solvate thereof. The present invention also provides pharmaceutical compositions containing such a salt or prepared using such a salt, processes and intermediates for the preparation of such a salt, and methods of using such a salt in the treatment of a pulmonary disorder.

CY20131100115T 2004-08-16 2013-02-08 THE CRYSTAL FORM OF A BINDING UNION CY1113646T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60180504A 2004-08-16 2004-08-16
EP05803280A EP1778672B1 (en) 2004-08-16 2005-08-15 Crystalline form of a biphenyl compound

Publications (1)

Publication Number Publication Date
CY1113646T1 true CY1113646T1 (en) 2016-06-22

Family

ID=58448833

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100115T CY1113646T1 (en) 2004-08-16 2013-02-08 THE CRYSTAL FORM OF A BINDING UNION

Country Status (1)

Country Link
CY (1) CY1113646T1 (en)

Similar Documents

Publication Publication Date Title
MA28825B1 (en) CRYSTAL FORM OF BIPHENYL COMPOUND
EA200801691A1 (en) AMBER SALT 1- [2- (2-CHLOR-4 - {[(R) -2-HYDROXY-2- (8-HYDROXY-2-OXO-1,2-DIGIRDOHINOLIN-5-IL) ETYLAMINO] METHYL} -5-METHOXIFENILKARBAMOIL) ETILE] PIPERIDIN-4-ILO ETHER BIPHENYL-2-ILKARBAMINIC ACID AND ITS APPLICATION FOR THE TREATMENT OF PULMONARY DISORDERS
CY1111197T1 (en) TRIAZOLS USEFUL AS PROTEIN SUSPENDMENTS
EA201001769A1 (en) DERIVATIVES OF QUINOLINES AND QUINOXALINS AS PROTEINTHYROSINKINASE INHIBITORS
CY1115176T1 (en) TOLL TYPE RECEPTOR ADJUSTERS
CY1111275T1 (en) Crystalline form of a quinolin-carboxamide compound
CY1110221T1 (en) STANDARD Sodium Pharmaceutical Formulations MODELUKASTIS
DE602005007339D1 (en) NEBIVOLOL AND ITS NON-PHARMACEUTICAL SALTS, METHOD OF MANUFACTURE AND PHARMACEUTICAL COMPOSITIONS OF NEBIVOLOL
EA200602196A1 (en) DERIVATIVES OF PYRAZOL, COMPOSITIONS CONTAINING THESE CONNECTIONS AND METHODS OF APPLICATION
CY1109227T1 (en) Derivative of 5-phenyl-4-methyl-thiazol-2-yl-amine as Inhibitors of the Phosphatidylinositol 3 (P13) Thionyl Methyl Enzyme (P13) Thionyl
EA200501713A1 (en) PHENYL SUBSTITUTE CARBONIC ACIDS
NO20091892L (en) Crystalline form of (3S) -3- (N- (N'- (2-tert-butylphenyl) oxamyl) alaninyl) amino-5- (2`, 3`, 5`, 6'-tetrafluorophenoxy) -4-oxopentanoic acid
BRPI0513713A (en) piperazine derivatives useful for the treatment of gastrointestinal disorders
EA200501710A1 (en) SUBSTITUTED CARBON ACIDS
EA200970124A1 (en) DERIVATIVES 2-ARILINDOL AS NPGES-1 INHIBITORS
ATE504580T1 (en) MALONIC ACID AMIDE DERIVATIVES AS INHIBITORS OF G-SECRETASE FOR THE TREATMENT OF ALZHEIMER'S DISEASE
RU2008129723A (en) CCR9 ACTIVITY INHIBITORS
SE0402925D0 (en) Novel Compounds
CY1113622T1 (en) Crystalline form of a compound 4- [2- (2-fluorophenoxymethyl) phenyl] piperidine
BRPI0408466B8 (en) pharmaceutical composition and use of cholesteryl ester and crospovidone transfer protein inhibitor
EA201992744A1 (en) PHARMACEUTICAL COMPOSITIONS N- (2- (2- (DIMETHYLAMINO) ETOXY) -4-METOXY-5 - ((4- (1-METHYL-1H-INDOL-3-IL) PYRIMIDIN-2-IL) AMINO) Phenyl) Acrylamide AND HIS SALTS
ATE444069T1 (en) QUINOLINE DERIVATIVES FOR THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISEASES
CY1112012T1 (en) Amino Acid Derivatives of B-HM and B-Heteroandrostanes
CY1113646T1 (en) THE CRYSTAL FORM OF A BINDING UNION
DE602005007604D1 (en) DIASTEREOSELECTIVE ADDITION OF LITHIATED N-METHYLIMIDAZOLE ON SULFINIMINES